Bombesin analogs containing α-amino-isobutyric acid with potent anticancer activity

Journal of Peptide Science

Volumn 13, Issue 1, 2007, Pages 54-62

  Prasad, Sudhanand ^a   Mathur, Archna ^a   Gupta, Neena ^a   Jaggi, Manu ^a   Singh, Anu T ^a   Rajendran, Praveen ^a   Sanna, Vinod K ^a   Datta, Kakali ^a   Mukherjee, Rama ^a  

^a DABUR RESEARCH FOUNDATION   (India)

Author keywords

amino isobutyric acid; Anticancer; Bombesin; Peptides

Indexed keywords

2 AMINOBUTYRIC ACID; ANTINEOPLASTIC AGENT; BOMBESIN DERIVATIVE; BUTANOYL DEXTRO PHENYLGLUTAMYLTRYPTOPHANYLALANYLVALYL ALPHA AMINOISOBUTYRIC ACID HISTIDYLLEUCYLAMIDE; DEXTRO PHENYLGLUTAMYLTRYPTOPHANYL ALPHA AMINOISOBUTYRIC ACID VALYL ALPHA AMINOISOBUTYRIC ACID HISTIDYLLEUCYLAMIDE; DEXTRO PHENYLGLUTAMYLTRYPTOPHANYL ALPHA AMINOISOBUTYRIC ACID VALYLGLYCYLHISTIDYLISOLEUCYLAMIDE; DEXTRO PHENYLGLUTAMYLTRYPTOPHANYL ALPHA AMINOISOBUTYRIC ACID VALYLGLYCYLHISTIDYLLEUCYLAMIDE; DEXTRO PHENYLGLUTAMYLTRYPTOPHANYLALANYLVALYL ALPHA AMINOISOBUTYRIC ACID HISTIDYLISOLEUCYLAMIDE; DEXTRO PHENYLGLUTAMYLTRYPTOPHANYLALANYLVALYL ALPHA AMINOISOBUTYRIC ACID HISTIDYLLEUCYLAMIDE; DEXTRO PHENYLGLUTAMYLTRYPTOPHANYLALANYLVALYLGLYCYLHISTIDYLLEUCYLAMIDE; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; COLON CANCER; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG DESIGN; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; HUMAN; HUMAN CELL; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; NUDE MOUSE; PRIORITY JOURNAL; TUMOR REGRESSION; TUMOR VOLUME; TUMOR XENOGRAFT;

AMINO ACID SEQUENCE; AMINOISOBUTYRIC ACIDS; ANIMALS; ANTINEOPLASTIC AGENTS; BOMBESIN; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; HT29 CELLS; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MICE; MICE, INBRED BALB C; MICE, NUDE; MODELS, MOLECULAR; MOLECULAR STRUCTURE; STRUCTURE-ACTIVITY RELATIONSHIP; THERMODYNAMICS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS MUSCULUS;

EID: 33846706186     PISSN: 10752617     EISSN: 10991387     Source Type: Journal    
DOI: 10.1002/psc.799     Document Type: Article

References (44)

1. Anastasi A, Erspamer V, Bucci H. Isolation and structure of bombesin and alytesin, two analogous active peptides from the skin of the European amphibians Bombina and Alytes. Experientia 1971; 27: 166-168.
2. Kroog GS, Jensen RT, Battey JF. Mammalian bombesin receptors. Med. Res. Rev. 1995; 15: 389-417.
3. 14] bombesin(6-14). Clin. Cancer Res. 2002; 8: 1139-1146.
4. Reubi JC. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr. Rev. 2003; 24: 389-427.
5. Rozengurt E. Bombesin stimulation of mitogenesis. Specific receptors, signal transduction, and early events. Am. Rev. Respir. Dis. 1990; 142(6 Pt 2): S11-S15.
6. Cuttitta F, Carney DN, Mulshine J, Moody TW, Fedorko J, Fischler A, Minna JD. Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancer. Nature 1985; 316: 823-826.
7. Moody TW, Carney DN, Cuttitta F, Quattrocchi K, Minna JD. High affinity receptors for bombesin/GRP-like peptides on human small cell lung cancer. Life Sci. 1985; 37: 105-113.
8. Markwalder R, Reubi JC. Gastrin-releasing peptide receptors in the human prostate: relation to neoplastic transformation. Cancer Res. 1999; 59: 1152-1159.
9. Gugger M, Reubi JC. Gastrin-releasing peptide receptors in non-neoplastic and neoplastic human breast. Am. J. Pathol. 1999; 155: 2067-2076.
10. Burghardt B, Wenger C, Barabas K. Racz G, Olah A, Flautner L, Coy DH, Gress TM, Varga G. GRP-receptor mediated signal transduction, gene expression and DNA synthesis in the human pancreatic adenocarcinoma cell line HPAF. Peptides, 2001; 22: 1119-1128.
11. Carroll RE, Ostrovskiy D, Lee S, Danilkovich A, Benya RV. Characterization of gastrin-releasing peptide and its receptor aberrantly expressed by human colon cancer cell lines. Mol. Pharmacol. 2000; 58: 601-607.
12. Zhou J, Chen J, Mokotoff M, Ball ED. Targeting gastrin-releasing peptide receptors for cancer treatment. Anti-Cancer Drugs 2004; 15: 921-927.
13. 2 or its derivatives. Proc. Natl. Acad. Sci. U S A. 1994; 91: 12664-12668.
14. Coy DH, Jensen RT, Jiang NY. Systematic development of bombesin/ gastrin-releasing peptide antagonists. J. Natl. Cancer Inst. Monogr. 1992; 13: 133-139.
15. Manley SA, Coy DH, Entsuah LK, Jensen RT. Development of bombesin analogs with conformationally restricted amino acid substitutions with enhanced selectivity for the orphan receptor human bombesin receptor subtype 3. J. Pharmacol. Exp. Ther. 2004; 310: 1161-1170.
16. Pradhan TH, Katsuno T, Taylor JE, Kim SH, Ryan PR, Mantey SA, Donohue PJ, Weber HC, Sainz E, Battey JF, Coy DH, Jensen RT. Identification of a unique ligand which has high affinity for all four bombesin receptor sub-types. Eur. J. Pharmacol. 1998; 343: 275-287.
17. Qin Y, Ertl T, Cai RZ, Horvath JE, Groot K, Schally AV. Antagonists of bombesin/gastrin-releasing peptide inhibit growth of SW-1990 human pancreatic adenocarcinoma and production of cyclic AMP. Int. J. Cancer 1995; 63: 257-262.
18. Qin Y, Ertl T, Cai RZ, Halmos G, Schally AV. Inhibitory effect of bombesin receptor antagonist RC-3095 on the growth of human pancreatic cancer cells in vivo and in vitro. Cancer Res. 1994; 54: 1035-1041.
19. Schally AV, Nagy A. Cancer chemotherapy based on targeting of cytotoxic peptide conjugates to their receptors on tumors. Eur. J. Endocrinol. 1999; 141: 1-14.
20. Nagy A, Schally AV. Targeting cytotoxic conjugates of somatostatin, luteinizing hormone-releasing hormone and bombesin to cancers expressing their receptors: a smarter chemotherapy. Curr. Pharm. Des. 2005; 11: 1167-1180.
21. Safavy A, Raisch KP, Khazaeli MB, Buchsbaum DJ, Bonner JA. Paclitaxel derivatives for targeted therapy of cancer: toward the development of smart taxanes. J. Med. Chem. 1999; 42: 4919-4924.
22. Moody TW, Mantey SA, Pradhan TK, Schumann M, Nakagawa T, Martinez A, Fuselier J, Coy DH, Jensen RT. Development of high affinity camptothecin-bombesin conjugates that have targeted cytotoxicity for bombesin receptor-containing tumor cells. J. Biol. Chem. 2004; 279: 23580-23589.
23. 111In-labeled DTPA- or DOTA-bombesin analogues for receptor-targeted scintigraphy and radionuclide therapy. J. Nucl. Med. 2002; 43: 1650-1656.
24. Smith CJ, Volkert WA, Hoffman TJ. Gastrin-releasing peptide (GRP) receptor targeted radiopharmaceuticals: a concise update. Nucl. Med. Biol. 2003; 30: 861-868.
25. Varvarigou A, Bouziotis P, Zikos C, Scopinaro F, De Vincentis G. Gastrin-releasing peptide (GRP) analogues for cancer imaging. Cancer Biother. Radiopharm. 2004; 19: 219-229.
26. Nock BA, Nikolopoulou A, Galanis A, Cordopatis P, Waser B, Reubi JC, Maina T. Potent bombesin-like peptides for GRP-receptor targeting of tumors with 99mTc: a pre-clinical study. J. Med. Chem. 2005; 48: 100-110.
27. Karle IL, Balaram P. Structural characteristics of alpha-helical peptide molecules containing Aib residues, Biochemistry 1990; 29; 6747-6756.
28. Toniolo C, Crisma M, Valle G, Bonora GM, Polinelli S, Becker EL, Freer RJ, Prasad S, Rao RB, Balaram P. Coformationally restricted formyl methionyl tripeptide chemoattractants: a three-dimensional structure-activity study of analogs incorporating a C-alpha, alpha-dialkylated glycine at position 2. Pept. Res. 1989; 2: 275-281.
29. Prasad S, Rao RB, Bergsstand H, Lindquist B, Becker EI, Balaram P. Conformation-activity correlations for chemotactic tripeptide analogs incorporating α, α-dialkylated residues with linear and cyclic side chains at position 2. Int. J. Pept. Protein Res. 1996; 48: 312-318.
30. Prasad S, Mathur A, Sharma R, Gupta N, Ahuja R, Jaggi M, Singh AT, Mukherjee R. Octapeptide analogs of somatostatin containing α, α-dialkylated amino acids with potent anticancer activity. Int. J. Pept. Res. Ther. 2006; 12: 179-185.
31. Zompra AA, Magafa V, Lamari FN, Nikolopoulou A, Nock B, Maina T, Spyroulias GA, Karamanos NK, Cordopatis P. GnRH analogs containing conformationally restricted amino acids in positions 3 and 6: differential impact on pituitary binding affinity and direct antiproliferative effect on breast cancer cells. J. Pept. Res. 2006; 66: 57-64.
32. Naoto S, Guo J, Gardella TJ. Parathyroid hormone (PTH)-(1 - 14) and-(1 - 11) analogs conformationally constrained by α-aminoisobutyric acid mediate full agonist responses via the juxtamembrane region of the PTH-1 receptor. J. Biol. Chem. 2001; 52: 49003-49012.
33. 17) VIP hybrid antagonizes VIP receptors on non small cell lung cancer cells. Life Sci. 1997; 61: 1657-1666.
34. Dasgupta P, Singh AT, Mukherjee R. N-terminal acylation of somatostatin analog with long chain fatty acids enhances its stability and anti-proliferative activity in human breast adenocarcinoma cells. Biol. Pharm. Bull. 2002; 25: 29-36.
35. Dasgupta P, Singh AT, Mukherjee R. Lipophilization of somatostatin analog RC-160 with long chain fatty acid improves its anti-proliferative activity on human oral carcinoma cells in vitro. Life Sci. 2000; 66: 1557-1570.
36. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immounol. Methods 1983; 65: 55-63.
37. Jaggi M, Mukherjee R. Development and successful transfer of human colon adenocarcinomas in vitro and in vivo models. J. Basic Appl. Biomed. 1995; 3: 27-35.
38. Lin J-T, Coy DH, Manley SA, Jensen RT. Comparison ofthe peptide structural requirements for high affinity interaction with bombesin receptors. Eur. J. Pharmacol. 1995; 294: 55-69.
39. Heimbrook DC, Boyer ME, Garsky VM, Balishin NL, Kiefer DM, Oliff A, Riemen MW. Minimal ligand analysis of gastrin releasing peptide. J. Biol. Chem. 1988; 15: 7016-7019.
40. Carver JA, Collins JG. NMR identification of a partial helical conformation for bombesin in solution. Eur. J. Biochem. 1990; 187: 645-650.
41. Jaggi M, Singh AT, Prasad S, Rajendran P, Dutt S, Burman AC, Mukherjee R. Anticancer activity of DRF7295: A peptide combination targeting multiple neuropeptide receptors in gastrointestinal cancers. Clin. Cancer Res. 2005; 11: 9081S-9082S.
42. Condamine E, Chapdeleine G, Demarcy L, Duclos J-F, Davoust D, Llinares M, Azay J, Martinez J, Chapelle S. Biological activity and three-dimensional structure of an agonist analog of bombesin. J. Pept. Res. 1998; 51: 55-64.
43. Carver JA. The conformation of bombesin in solution as determined by two-dimensional 1H-NMR techniques. Eur. J. Biochem. 1987; 168: 193-199.
44. Di Bello C, Gozzini L, Corradini MG, D'Auria G, Paolillo L, Trivellone E. 500 MHz NMR characterization of synthetic bombesin and related peptides in DMSO-d6 by two-dimensional techniques. FEBS Lett. 1988; 237: 85-90.